Experimental study of COX-2 selective and traditional non-steroidal anti-inflammatory drugs in total hip replacement

Journal of International Medical Research

Volumn 37, Issue 2, 2009, Pages 472-478

  Li, W ^a   Lian, Y Y ^a   Yue, W J ^a   Yang, Qi ^a   Yue, Qi ^a   Meng, Qing Gang ^a   Zhao, C B ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Arthroplasty; Enteric coated diclofenac; Non steroidal anti inflammatory drugs (NSAIDs); Peri operative blood loss; Rofecoxib; Surgery; Total hip replacement

Indexed keywords

DICLOFENAC; PLACEBO; ROFECOXIB; CYCLOOXYGENASE 2; LACTONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; SULFONE;

ADULT; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SELECTIVITY; DRUG WITHDRAWAL; ELECTIVE SURGERY; ENTERIC COATED TABLET; EXPERIMENTAL STUDY; FEMALE; HUMAN; MALE; PAIN; PERIOPERATIVE PERIOD; PREOPERATIVE TREATMENT; RANDOMIZED CONTROLLED TRIAL; SURGICAL TECHNIQUE; TOTAL HIP PROSTHESIS; UNSPECIFIED SIDE EFFECT; DEMOGRAPHY; HIP ARTHROPLASTY; METABOLISM; MIDDLE AGED; PATIENT PARTICIPATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHROPLASTY, REPLACEMENT, HIP; BLOOD LOSS, SURGICAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DEMOGRAPHY; DICLOFENAC; FEMALE; HUMANS; LACTONES; MALE; MIDDLE AGED; PATIENT PARTICIPATION; SULFONES; SURGICAL PROCEDURES, ELECTIVE;

EID: 66649113775     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700223     Document Type: Article

References (34)

1. Mahon JL, Bourne RB, Rorabeck CH, et al: Health-related quality of life and mobility of patients awaiting elective total hip arthroplasty: a prospective study. CMAJ 2002; 167: 1115-1121.
2. Nuñez M, Nuñez E, Segur JM, et al: The effect of an educational program to improve health-related quality of life in patients with osteoarthritis on waiting list for total knee replacement: a randomized study. Osteoarthritis Cartilage 2006; 14: 279-285.
3. Ethgen O, Bruyère O, Richy F, et al: Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg Am 2004; 86: 963-974.
4. Kokoszka P, Staszczuk P, Redman M, et al: Evaluation of outcomes following total hip arthroplasty. Chir Narzadow Ruchu Ortop Pol 2008; 73: 94-100 [in Polish, English abstract].
5. Dechartes A, Boutron I, Nizard R, et al: Knee arthroplasty: disabilities in comparison to the general population and to hip arthroplasty using a French national longitudinal survey. PLoS ONE 2008; 3: e2561.
6. Tian H, Song F, Zhang K, et al: Efficacy and safety of aspirin in prevention of venous thromboembolism after total joint arthroplasty. Zhonghua Yi Xue Za Zhi 2007; 87: 3349-3352 [in Chinese].
7. Schafer A: Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 1995; 35: 209-219.
8. Campbell WI, Kendrick R, Patterson C: Intravenous diclofenac sodium. Does its administration before operation suppress postoperative pain? Anaesthesia 1990; 45: 763-766.
9. Rorarius MG, Baer GA, Metsä-Ketelä T, et al: Effects of peri-operatively administered diclofenac and indomethacin on blood loss, bleeding time and plasma prostanoids in man. Eur J Anaesthesiol 1989; 6: 335-342.
10. Vane JR, Botting RM: New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995; 44: 1-10.
11. Gawlewicz-Mroczka A, Gielicz A, Mastalerz L, et al: Prostaglandin E2: metabolism, determination in body fluids and the role in aspirin hypersensitivity. Pol Arch Med Wewn 2006; 115: 578-586 [in Polish].
12. Giovanni G, Giovanni P: Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects? J Nephrol 2002; 15: 480-488.
13. McKenna F: COX-2 separating myth from reality. Scand J Rheumatol Suppl 1999; 109: 19-29.
14. Adebayo D, Bjarnason I: Is non-steroidal anti-inflammatory drug (NSAID) enteropathy clinically more important than NSAID gastropathy? Postgrad Med J 2006; 82: 186-191.
15. Santos LL, Morand EF: The role of macrophage migration inhibitory factor in the inflammatory immune response and rheumatoid arthritis. Wien Med Wochenschr 2006; 156: 11-18.
16. Catella-Lawson F, Reilly MP, Kapoor SC, et al: Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001: 345: 1809-1817.
17. Cryer B, Feldman M: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammotry drugs. Am J Med 1998; 104: 413-421.
18. Engelhard G, Bögel R, Schnitzler C, et al: Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings. Biochem Pharmacol 1996; 51: 29-38.
19. Sorbera LA, Leeson PA, Castaner J: Rofecoxib. Anti-inflammatory cyclooxygenase-2 inhibitor. Drugs Future 1998; 23: 1287-1296.
20. Langman MJ, Jensen DM, Watson DJ, et al: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929-1933.
21. Scott LJ, Lamb HM: Rofecoxib. Drugs 1999; 58: 499-505.
22. Bombardier C, Laine L, Reicin A, et al: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528.
23. Watson DJ, Harper SE, Zhao PL, et al: Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared in osteoarthritis. Arch Intern Med 2000; 160: 2998-3003.
24. Clemett D, Goa KL: Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain Drugs 2000; 59: 957-980.
25. Merck & Co. Inc: Merck announces voluntary worldwide withdrawal of Vioxx®. News Release, Whitehouse Station: Merck, 30 September 2004 (available at http://www.merck.com/newsroom/vioxx/pdf/ vioxx_press_release_final.pdf).
26. Depré M, Ehrich E, Van Hecken A, et al: Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur J Clin Pharmacol 2000; 56: 167-174.
27. Chan CC, Boyce S, Brideau C, et al: Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone]: a potent and orally active cylooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999; 290: 551-560.
28. Wong M, Jiang BY, McNeill K, et al: Effects of selective and non-selective cyclo-oxygenase inhibition on endothelial function in patients with rheumatoid arthritis. Scand J Rheumatol 2007; 36: 265-269.
29. Ehrich EW, Dallob A, De Lepeleire J, et al: Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999; 65: 336-347.
30. Morrison BW, Christensen S, Yuan W, et al: Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized controlled trial. Clin Ther 1999; 21: b 943-953.
31. Morrison BW, Daniels SE, Kotey P, et al: Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 1999; 94: 504-508.
32. Reicin A, Brown J, Jove M, et al: Efficacy of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain. Am J Orthop 2001; 30: 40-48.
33. Weber EW, Slappendel R, Durieux ME, et al: COX 2 selectivity of non-steroidal anti-inflammatory drugs and perioperative blood loss in hip surgery. A randomized comparison of indomethacin and meloxicam. Eur J Anaesthesiol 2003; 20: 963-966.
34. Sawicka-Powierza J, Oltarzewska AM, Chlabicz S: Haemorrhagic complications among patients on life-long acenocumarol therapy. Przegl Lek 2008; 65: 340-344 [in Polish].